High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 44, 2012, Pages 18066-18071

  Mazzoni, Elisa ^a   Corallini, Alfredo ^a   Cristaudo, Alfonso ^b   Taronna, Angelo ^a   Tassi, Gianfranco ^c   Manfrini, Marco ^a   Comar, Manola ^d   Bovenzi, Massimo ^e   Guaschino, Roberto ^f   Vaniglia, Francesca ^g   Magnani, Corrado ^h   Casali, Ferruccio ⁱ   Rezza, Giovanni ^j   Barbanti Brodano, Giuseppe ^a   Martini, Fernanda ^a   Tognon, Mauro G ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c United Hospitals   (Italy)

^d INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

^f C Arrigo Children's Hospital   (Italy)

^g City Hospital of Casale Monferrato   (Italy)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ Clinical Laboratory Analysis   (San Marino)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

Antibody; Neoplasia

Indexed keywords

ANTIBODY; ASBESTOS; ASBESTOS FIBER; CAPSID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SIMIAN VIRUS 40; VIRUS ISOLATION;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MESOTHELIOMA; MOLECULAR SEQUENCE DATA; PLEURAL NEOPLASMS; PREGNANCY; SIMIAN VIRUS 40;

MIRIDAE; SIMIAN VIRUS 40;

EID: 84868109819     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213238109     Document Type: Article

References (62)

1. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366(9483): 397-408.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79(3-4):666-672.
3. Ismail-Khan R, et al. (2006) Malignant pleural mesothelioma: A comprehensive review. Cancer Contr 13(4):255-263.
4. Zucali PA, Giaccone G (2006) Biology and management of malignant pleural mesothelioma. Eur J Cancer 42(16):2706-2714.
5. Zucali PA, et al. (2010) New tricks for old biomarkers: Thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 21(7): 1560-1561.
6. Pass HI, et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15):1564-1573.
7. Robinson BW, et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396):1612-1616.
8. Paleari L, et al. (2009) Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 24(2):112-117.
9. Rodríguez Portal JA, et al. (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18(2):646-650.
10. Varani K, et al. (2011) A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. Am J Respir Crit Care Med 183(4):522-530.
11. Balatti V, et al. (2011) MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol 6(5):844-851.
12. Klein G, Powers A, Croce C (2002) Association of SV40 with human tumors. Oncogene 21(8):1141-1149.
13. Cristaudo A, et al. (2005) SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study. Cancer Res 65(8):3049-3052.
14. Pietruska JR, Kane AB (2007) SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67(8):3637-3645.
15. Robinson C, et al. (2006) A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: Malignant transformation is dose dependent. Cancer Res 66(22): 10786-10794.
16. Kroczynska B, et al. (2006) Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103 (38):14128-14133.
17. Zucali PA, et al. (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37(7):543-558.
18. Bott M, et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7):668-672.
19. Testa JR, et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022-1025.
20. Barbanti-Brodano G, et al. (2004) Simian virus 40 infection in humans and association with human diseases: Results and hypotheses. Virology 318(1):1-9.
21. López-Ríos F, Illei PB, Rusch V, Ladanyi M (2004) Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440): 1157-1166.
22. Henzi T, et al. (2009) SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 174(6):2324-2336.
23. Ribeiro T, et al. (2010) Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. Neurol Sci 31(4):517-521.
24. Lundstig A, et al. (2005) Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol 86(Pt 6):1703-1708.
25. Viscidi RP, et al. (2003) Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10(2):278-285.
26. Barbanti-Brodano G, Corallini A, Accolla RS, Martini F, Tognon M (2004) Re: Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 96(10):803-804.
27. Carter JJ, et al. (2003) Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95(20):1522-1530.
28. Kjaerheim K, et al. (2007) Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer 120(11):2459-2465.
29. Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5(3):e1000363.
30. Bouvard V, et al.; WHO International Agency for Research on Cancer Monograph Working Group (2012) Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol 13(4):339-340.
31. Martini F, et al. (2007) Simian virus 40 in humans. Infect Agent Cancer 2:13.
32. Stratton K, Almario DA, McCormick MC, eds (2003) Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (Natl Acad Press, Washington, DC)
33. Corallini A, et al. (2012) Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol 73(5): 502-510.
34. Maeda M, et al. (2010) Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 7(4):268-278.
35. Tulinska J, et al. (2004) Immunomodulatory effects of mineral fibres in occupationally exposed workers. Mutat Res 553(1-2):111-124.
36. Chang D, et al. (1996) Genotypes of human polyomaviruses in urine samples of pregnant women in Taiwan. J Med Virol 48(1):95-101.
37. Butel JS, Arrington AS, Wong C, Lednicky JA, Finegold MJ (1999) Molecular evidence of simian virus 40 infections in children. J Infect Dis 180(3):884-887.
38. Butel JS, et al. (1999) Evidence of SV40 infections in hospitalized children. Hum Pathol 30(12):1496-1502.
39. Comar M, Zanotta N, Bovenzi M, Campello C (2010) JCV/BKV and SV40 viral load in lymphoid tissues of young immunocompetent children from an area of north-east Italy. J Med Virol 82(7):1236-1240.
40. Jafar S, Rodriguez-Barradas M, Graham DY, Butel JS (1998) Serological evidence of SV40 infections in HIV-infected and HIV-negative adults. J Med Virol 54(4):276-284.
41. Li RM, et al. (2002) Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 13(9):2320-2330.
42. Li RM, et al. (2002) BK virus and SV40 co-infection in polyomavirus nephropathy. Transplantation 74(11):1497-1504.
43. Patel NC, et al. (2008) Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol 43(1):66-72.
44. Vanchiere JA, White ZS, Butel JS (2005) Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol 75(3):447-454.
45. Vanchiere JA, et al. (2009) Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol 47(8):2388-2391.
46. Melnick JL, Stinebaugh S (1962) Excretion of vacuolating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med 109:965-968.
47. Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V (1961) Clinical and serologic responses in volunteers given vacuolating virus (SV-40) by respiratory route. Proc Soc Exp Biol Med 108:56-59.
48. Pancaldi C, et al. (2009) Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect 58(1):53-60.
49. Bocchetta M, et al. (2000) Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 97(18):10214-10219.
50. Cacciotti P, et al. (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98(21):12032-12037.
51. Morelli C, Barbisan F, Iaccheri L, Tognon M (2004) Simian virus 40 persistent infection in long-term immortalized human fibroblast cell lines. J Neurovirol 10(4):250-254.
52. Mazzoni E, et al. (2012) Simian virus 40 efficiently infects human T lymphocytes and extends their lifespan. Exp Hematol 40(6):466-476.
53. Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo' G (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 30(5): 751-777.
54. Swetly P, Brodano GB, Knowles B, Koprowski H (1969) Response of simian virus 40- transformed cell lines and cell hybrids to superinfection with simian virus 40 and its deoxyribonucleic acid. J Virol 4(4):348-355.
55. Portolani M, Marzocchi A, Barbanti-Brodano G, La Placa M (1974) Prevalence in Italy of antibodies to a new human papovavirus (BK virus). J Med Microbiol 7(4):543-546.
56. Maraldi NM, Barbanti-Brodano G, Portolani M, La Placa M (1975) Ultrastructural aspects of BK virus uptake and replication in human fibroblasts. J Gen Virol 27(1):71-80.
57. Major EO, et al. (1985) Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA 82(4):1257-1261.
58. Neel JV, et al. (1996) Hypothesis: "Rogue cell"-type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Proc Natl Acad Sci USA 93(7):2690-2695.
59. Barbanti-Brodano G, et al. (2004) Reactivation of infectious simian virus 40 from normal human tissues. J Neurovirol 10(3):199-205.
60. Stehle T, Gamblin SJ, Yan Y, Harrison SC (1996) The structure of simian virus 40 refined at 3.1 Å resolution. Structure 4(2):165-182.
61. Bernstein HJ (2000) Recent changes to RasMol, recombining the variants. Trends Biochem Sci 25(9):453-455.
62. Sayle RA, Milner-White EJ (1995) RASMOL: Biomolecular graphics for all. Trends Biochem Sci 20(9):374-376.